Regenicin, Inc.
RGIN
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 233.10K | 267.60K | 146.40K | 152.70K | 155.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 327.80K | 267.60K | 146.40K | 152.70K | 155.50K |
| Operating Income | -327.80K | -267.60K | -146.40K | -152.70K | -155.50K |
| Income Before Tax | -336.40K | -277.50K | -155.40K | -163.10K | -166.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -336.40K | -277.50K | -155.40K | -163.10K | -166.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -336.40K | -277.50K | -155.40K | -163.10K | -166.60K |
| EBIT | -327.80K | -267.60K | -146.40K | -152.70K | -155.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 153.48M | 153.48M | 153.48M | 153.48M | 153.48M |
| Average Diluted Shares Outstanding | 153.48M | 153.48M | 153.48M | 153.48M | 153.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |